Market Overview

UPDATE: SunTrust Robinson Humphrey Reiterates on Hologic as Deterioration Story Gains Momentum

Share:
Related HOLX
Strength Of Surgical Segment Helps Hologic To A Strong Q3
Benzinga's Top Upgrades

In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan reiterated a Reduce rating on Hologic (NASDAQ: HOLX), but lowered the price target from $17.00 to $15.00.

In the report, SunTrust Robinson Humphrey noted, “New guidance for FY14 reflects the reality of deteriorating end markets and only the beginning of significant margin pressure in the years ahead. Declining EBITDA and a two year delay in leverage target guidance are similarly of high concern. Hopes for a return to growth by FY15 look entirely unrealistic to us, and we lower our PT from $17 to $15 in order to reflect what we view as notably greater risk.”

Hologic closed on Monday at $22.90.

Latest Ratings for HOLX

DateFirmActionFromTo
Jul 2016Morgan StanleyMaintainsEqual-weight
Jul 2016JefferiesMaintainsBuy
Jul 2016Evercore ISI GroupUpgradesHoldBuy

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: Amit Hazan SunTrust Robinson HumphreyAnalyst Color Price Target Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!